# UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

> **NCT07648225** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The United Bio-Technology (Hengqin) Co., Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- Obesity & Overweight

## Interventions

- **DRUG:** UBT251 Injection 4.0 mg
- **DRUG:** UBT251 Injection 6.0 mg
- **DRUG:** UBT251 Injection Placebo 4.0 mg
- **DRUG:** UBT251 Injection Placebo 6.0 mg

## Key facts

- **NCT ID:** NCT07648225
- **Lead sponsor:** The United Bio-Technology (Hengqin) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-09-29
- **Final completion:** 2027-11-03
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648225, "UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07648225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*